Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$76.25

0.02 (0.03%)

06:48
02/13/18
02/13
06:48
02/13/18
06:48

Eli Lilly announces 'positive' top-line results for Taltz

Eli Lilly announced that Taltz met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis, or AS, also known as radiographic axial spondyloarthritis, or axSpA. The trial included a placebo arm and an active control arm, or adalimumab, for comparison with placebo, and studied patients who had never received a biologic disease-modifying anti-rheumatic drug, or bDMARD. Taltz demonstrated a statistically significant improvement in the signs and symptoms of AS, as measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society 40, or ASAS40, response at 16 weeks, when compared to placebo. COAST-V is the first registration trial to use ASAS40 as the primary endpoint, compared to the standard endpoint of ASAS20. AS is one type of spondyloarthritis that affects the pelvic joints and spine, and can be characterized by chronic inflammatory back pain, stiffness and impaired function and mobility. Of those affected by AS, approximately 80 percent will experience symptoms before age 30. In COAST-V, the incidence of treatment-emergent adverse events was similar with Taltz compared with placebo. The most common adverse events observed were consistent with the Phase 3 studies of ixekizumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. Lilly plans to submit detailed data from COAST-V for disclosure at scientific meetings and in peer-reviewed journals later this year. The company plans to submit for regulatory approvals pending additional data from the ongoing Taltz development program later this year.

  • 16

    Feb

  • 08

    Mar

  • 04

    Apr

  • 23

    Apr

LLY Eli Lilly
$76.25

0.02 (0.03%)

01/22/18
01/22/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Overweight at Atlantic Equities with analyst James Cordwell citing signs that iPhone demand is beginning to soften and emerging challenges to the smartphone's dominance. 2. General Electric (GE) downgraded to Neutral from Buy at BofA/Merrill with analyst Andrew Obin saying he expects management to lower 2018 guidance when it reports fourth quarter earnings on Wednesday. 3. American Express (AXP) downgraded to Neutral from Buy at Guggenheim with analyst Jeff Cantwell citing CCAR risk in 2018, the fact that its balance sheet is liability-sensitive, and the assumption that the company's provision expense will be significantly higher than expected in fiscal 2018. 4. Eli Lilly (LLY) downgraded to Underperform from Neutral at Credit Suisse with analyst Vamil Divan saying he does not believe Lilly is on track to hit its mid-term guidance of 5% annual sales growth from 2015-2020. 5. Symantec (SYMC) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick saying accelerating enterprise expectations do not square with mixed channel sentiment. The analyst also lowered his price target on the shares to $30 from $36. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
MSCO
01/29/18
INITIATION
Target $57
MSCO
Overweight
Radius Health initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison started Radius Health (RDUS) with an Overweight rating and $57 price target, contending that pricing and convenience offer a path for Radius' Tymlos to take share from market leader Forteo, sold by Eli Lilly (LLY). While Tymlos is launching well, Radius' patch development offers a path to long-term market expansion and elacestrant in breast cancer remains underappreciated by consensus, Harrison added.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/01/18
LEER
02/01/18
NO CHANGE
Target $98
LEER
Market Perform
Eli Lilly selloff an overreaction, says Leerink
Following Q4 results, updated 2018 tax and EPS guidance, Leerink analyst Seamus Fernandez tells investors that the pressure in Eli Lilly's shares was "surprising." The analyst views the move as an "overreaction" by investors, but acknowledges that 2018 poses some legitimate risks for diabetes and animal health franchises which we highlighted in an earlier note. It its "hard to get excited" given competitive headwinds, but valuation downside is limited, he contends. Fernandez reiterates a Market Perform rating on the stock, while raised his price target on the shares to $98 from $95 due to the benefit of tax.

TODAY'S FREE FLY STORIES

02:45
02/23/18
02/23
02:45
02/23/18
02:45
General news
FX Update: The dollar has traded moderately higher »

FX Update: The dollar…

02:05
02/23/18
02/23
02:05
02/23/18
02:05
General news
Asian Market Wrap: »

Asian Market Wrap: Asian…

PEG

PSEG

$49.18

0.65 (1.34%)

, COG

Cabot Oil & Gas

$23.88

0.63 (2.71%)

20:25
02/22/18
02/22
20:25
02/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PEG

PSEG

$49.18

0.65 (1.34%)

COG

Cabot Oil & Gas

$23.88

0.63 (2.71%)

HUN

Huntsman

$33.32

-0.27 (-0.80%)

CNK

Cinemark

$39.72

0.1 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Mar

  • 23

    May

DOVA

Dova Pharmaceuticals

$32.78

-0.08 (-0.24%)

19:57
02/22/18
02/22
19:57
02/22/18
19:57
Syndicate
Dova Pharmaceuticals 2.5M share Secondary priced at $32.00 »

JPMorgan, Jefferies and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    Feb

SPY

SPDR S&P 500 ETF Trust

$270.40

0.35 (0.13%)

, SPX

S&P 500

19:25
02/22/18
02/22
19:25
02/22/18
19:25
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Treasury Sec.: Trump…

SPY

SPDR S&P 500 ETF Trust

$270.40

0.35 (0.13%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMAB

OMA Airports

$41.47

0.33 (0.80%)

19:10
02/22/18
02/22
19:10
02/22/18
19:10
Hot Stocks
OMA Airports reports Q4 passenger traffic up 1.8% »

Total terminal passenger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIV

Aimco

$38.28

0.28 (0.74%)

19:05
02/22/18
02/22
19:05
02/22/18
19:05
Hot Stocks
Aimco acquires Bent Tree apartment community for $160M »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$3.60

-0.16 (-4.26%)

18:49
02/22/18
02/22
18:49
02/22/18
18:49
Hot Stocks
Kadmon updates 'positive' results from Phase 2 study of KD025 in cGVHD »

Kadmon announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASR

Asur

$182.83

1.49 (0.82%)

18:47
02/22/18
02/22
18:47
02/22/18
18:47
Hot Stocks
Asur reports Q4 passenger traffic down 4% »

ASUR's total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.27

-0.83 (-1.51%)

18:45
02/22/18
02/22
18:45
02/22/18
18:45
Periodicals
Judge criticizes U.S. Bancorp deal to sidestep prosecution, Bloomberg reports »

U.S. District Judge Lewis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 30

    May

KZIA

Kazia Therapeutics

$4.99

0.43 (9.43%)

18:36
02/22/18
02/22
18:36
02/22/18
18:36
Hot Stocks
Kazia granted orphan status for glioblastoma treatment »

The FDA granted Kazia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBE

Obsidian Energy

$0.98

0.0183 (1.91%)

18:29
02/22/18
02/22
18:29
02/22/18
18:29
Hot Stocks
Obsidian Energy reports 126% reserve replacement of 2017 production »

Obsidian Energy said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBE

Obsidian Energy

$0.98

0.0183 (1.91%)

18:27
02/22/18
02/22
18:27
02/22/18
18:27
Hot Stocks
Obsidian Energy names Jay Thornton chairman of the board »

Obsidian Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$8.33

0.06 (0.73%)

18:27
02/22/18
02/22
18:27
02/22/18
18:27
Earnings
SSR Mining reports Q4 adjusted EPS 2c, consensus 7c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SSRM

SSR Mining

$8.33

0.06 (0.73%)

18:21
02/22/18
02/22
18:21
02/22/18
18:21
Hot Stocks
SSR Mining sees 2018 gold production 340K gold equivalent ounces »

SSR Mining expect to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

IVC

Invacare

$17.97

-0.28 (-1.53%)

18:20
02/22/18
02/22
18:20
02/22/18
18:20
Hot Stocks
Invacare names Kathleen Leneghan as CFO, effective immediately »

Invacare announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SHCAY

Sharp

$8.21

-0.025 (-0.30%)

18:18
02/22/18
02/22
18:18
02/22/18
18:18
Periodicals
Sharp drops legal action against Hisense over TV brands, Nikkei reports »

Sharp has dropped legal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$40.91

0.35 (0.86%)

18:17
02/22/18
02/22
18:17
02/22/18
18:17
Periodicals
GM seeks South Korean aid to bolster local unit, Nikkei Asian Review reports »

General Motors is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$26.34

0.23 (0.88%)

18:14
02/22/18
02/22
18:14
02/22/18
18:14
Earnings
Breaking Earnings news story on South Jersey Industries »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

TRTN

Triton International

$28.16

-0.4 (-1.40%)

18:13
02/22/18
02/22
18:13
02/22/18
18:13
Earnings
Triton International reports Q4 adjusted EPS 85c, consensus 80c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SJI

South Jersey Industries

$26.34

0.23 (0.88%)

18:13
02/22/18
02/22
18:13
02/22/18
18:13
Earnings
Breaking Earnings news story on South Jersey Industries »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

PAA

Plains All American

$20.97

-0.43 (-2.01%)

18:09
02/22/18
02/22
18:09
02/22/18
18:09
Hot Stocks
Plains All American's Cactus II pipeline fully committed »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 07

    Mar

STX

Seagate

$51.36

-0.08 (-0.16%)

18:03
02/22/18
02/22
18:03
02/22/18
18:03
Initiation
Seagate initiated at Stifel »

Seagate resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WDC

Western Digital

$85.53

-0.14 (-0.16%)

18:01
02/22/18
02/22
18:01
02/22/18
18:01
Initiation
Western Digital initiated at Stifel »

Western Digital resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$21.39

0.22 (1.04%)

17:56
02/22/18
02/22
17:56
02/22/18
17:56
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 24

    Apr

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.